News
MIT Microscope Offers a Faster Look at Whole-Brain Electrical Activity
A new high-speed microscope from MIT could give neuroscientists a more direct way to observe how neurons communicate across an entire brain—an advance with implications for basic neuroscience, neurotechnology tool development, and future efforts to map distributed neural circuits in real time.
Briefings: Boston Scientific Recall, Nerve Stimulation for Sleep Apnea, Overactive Bladder, More
News from around the neurotech industry including Boston Scientific’s recall of Infinion CX lead, results from a hypoglossal nerve stimulation system trial, neural implants that work without batteries, vaginally-inserted, wireless neuromodulation device, cranioplasty implant and BCI connections receive FDA clearance, new US VP of Neuromodulation for Abbott, and more.
Neuromodulation Therapies Progress for the Treatment of Drug-Resistant Epilepsy
Over the past two decades, neuromodulation for drug-resistant epilepsy (DRE) has evolved from a single approved therapy—vagus nerve stimulation—into a broader field that includes responsive neurostimulation, deep brain stimulation, less-invasive cortical stimulation and emerging optical, thermal, and sensing-enabled systems. Antiseizure medications remain the first-line treatment, but approximately one-third of people with epilepsy continue to experience seizures despite pharmacologic therapy, creating a substantial unmet clinical need.
Computer Vision is Becoming Neurotech’s Situational Understanding Layer and Distribution Channel
Machine Medicine’s FDA breakthrough designation for their video assessment platform, hiring at Metamorphic and Epia Neuro, and a leaked Apple AirPods demo all point to the same patterns: computer vision can give better situational understanding and standardization in a world where human raters find challenges with consistency. Because cameras, LiDAR, and other types of spatial sensor systems are becoming inexpensive and ubiquitous, computer vision systems are increasingly easier to implement both in research settings and in everyday life.
Reach Neuro Reaches New Heights
Reach Neuro’s job board is empty for the moment. That is not an indication of the growth stage of the company. In fact, one could argue that the recent hiring of Jennifer Ernst as the firm’s new chief executive officer and engaging Jordi Parramon as the chairman of the board of directors is a signal that this is the calm before the storm. In fact, one of the stated goals in their current $1.5 million seed-round funding pitch calls for building a “Series A Fundable Team.”
Galvani Bioelectronics Publishes Splenic Nerve Pilot Study Results
UK-based Galvani Bioelectronics is working to develop a rheumatoid arthritis therapy using splenic nerve stimulation (SpNS). Initial results from the first 11 patients were published in The Lancet this month.
Lehigh Team Uses Digital Twin of Gut-Brain Axis to Advance Neurostimulation Therapies
A team of researchers at Lehigh University has developed one of the first comprehensive mathematical models of the neural circuitry linking the gut and brain, a “digital twin” designed to simulate how bidirectional signaling regulates stomach function. The work, described in Frontiers in Physiology, could help bioelectronic medicine researchers understand disorders of gut-brain interaction and accelerate the development of neuromodulation therapies such as vagus nerve stimulation.
Briefings from Epitel, Neurolief, ReVision, Aurenar, More
News from across the neurotech and bioelectronic medicine sector including funding for wireless EEG, 25 years of Implanted Pulse Generators, new patents for Autonomix, Transcutaneous Auricular Neurostimulation for menstrual bleeding, Percutaneous Electrical Nerve Field Stimulation, funding updates, and more.
Maria Bennett Shares Insights from SPR/Medtronic Merger
Earlier this summer, Medtronic announced that it completed its acquisition of SPR Therapeutics, Inc., the Cleveland, OH manufacturer of peripheral nerve stimulation systems for treating pain. The acquisition is valued at $650 million. NBR editor James Cavuoto sat down with SPR founder and CEO Maria Bennett at the recent meeting of the American Society of Pain and Neuroscience in Miami.
Researchers and Vendors Discuss Commercialization Issues at NYC Neuromodulation Conference
The 2026 NYC Neuromodulation Conference, held July 30 through August 3 at The City College of New York, underscored how quickly neuromodulation is moving from a research-driven field into a broader neurotechnology marketplace. The event was organized by Neuromodec and Marom Bikson, co-director of the Neural Engineering Lab and professor at CCNY. The meeting’s scientific agenda covered a range of topics, including noninvasive brain stimulation, TMS personalization, deep brain stimulation, spinal cord stimulation, autonomic and immune neuromodulation, computational modeling, home-based treatment paradigms, and evoked-response biomarkers—an agenda that mirrors many of the technical and reimbursement questions now facing neurotechnology companies.
